Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
NewVale Capital is a growth equity investment firm focused on investing in proven, revenue-generating life science services businesses that support the development, manufacturing, regulatory approval, and commercialization of medicines. The company does not develop therapeutics but invests in infrastructure providers critical to the life sciences industry. Its inaugural $167 million fund closed in 2024 with backing from institutional investors. Initial investments include Aizon (AI SaaS for pharma manufacturing), Argonaut Manufacturing Services (sterile fill/finish CDMO), and Beaconcure (clinical trial data validation software).
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on NewVale Capital.